Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 675.30K | 661.10K | 675.00K | 731.20K | 701.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 903.30K | 1.09M | 1.07M | 952.60K | 945.00K |
| Operating Income | -903.30K | -1.09M | -1.07M | -952.60K | -945.00K |
| Income Before Tax | -1.51M | -1.64M | -1.59M | -1.16M | -1.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.51 | -1.64 | -1.59 | -1.16 | -1.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.51M | -1.64M | -1.59M | -1.16M | -1.20M |
| EBIT | -903.30K | -1.09M | -1.07M | -952.60K | -945.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 213.26M | 200.06M | 189.28M | 176.81M | 169.86M |
| Average Diluted Shares Outstanding | 213.26M | 200.06M | 189.28M | 176.81M | 169.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |